Research programme: LEC/rituximab biobetter - Pivotal BioSciencesAlternative Names: PB 105
Latest Information Update: 23 Sep 2015
At a glance
- Originator Pivotal BioSciences
- Class Antineoplastics; Antirheumatics; Monoclonal antibodies
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 23 Sep 2015 Preclinical trials in Cancer in USA (Parenteral) before September 2015